
    
      Thrombotic event is one of the most serious complications in coronary artery disease, which
      often result in myocardial infarction and even death. Even according to the standard
      guidelines for antiplatelet therapy, there are still 6% to 15% of patients occur thrombotic
      events, in high-risk patients, the proportion is higher, this phenomenon is called
      anti-platelet drug resistance in clinical practice
    
  